San Jose, CA, USA. Jan. 11, 2016 QuanDx Inc., a biotechnology company developing and commercializing innovative molecular diagnostic tests for personalized cancer treatment, today announced that it has successfully completed its Series B2 financing round, raising $3.0 million. The funds will be used to continue development of the company’s proprietary platform technology and commercial program for molecular diagnostics in oncology, genetic diseases, and infectious diseases.
The successful closing of this second Series B financing continues to show the confidence our investors have for our proprietary technology and products as well as our continuing progress. This will now pave the way for the QuanDx team to greatly expand our R & D, marketing and sales network stated Matthew Lei, CEO of QuanDx.
Graeme Duncan, VP, Sales and Marketing commented, “The molecular diagnostics market is continuing to grow rapidly and QuanDx is now able to expand its marketing resources and personnel to focus on commercializing our rapidly developing product portfolio in 2016 and onwards. This will allow us to offer even greater options to patients and healthcare providers around the world.”
USA: Matthew Lei, Ph.D. President & CEO, Tel: +1 650-262-4140 Fax: +1 866 928-7828 Email:firstname.lastname@example.org
Europe: Graeme Duncan, Sales & Marketing Director, Tel: +44 7832 570742 Email: email@example.com